IP Library Patent Application 12955755
Patent Application
App. No. 12/955,755

METHODS OF INDUCING CELL DIFFERENTIATION WITH PLACENTAL EXTRACTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/955,755
Abstract

Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a “guided differentiation” program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.

Claims (47)

1 . A cell free extract capable of inducing differentiation in cancer cells, the cell free extract produced by the process comprising:

a. extracting human placenta;

b. homogenizing said placenta at a neutral pH, resulting in a homogenate;

c. centrifuging said homogenate in order to free the supernatant of cellular debris; and

d. purifying differentiation associated molecular weight fractions.

2 . The cell free extract of claim 1 wherein the differentiation-inducing fraction purified is of molecular weight of 10-10,000 Daltons.

3 . The cell free extract of claim 1 wherein the differentiation-inducing fraction purified is of molecular weight of 300-3,000 Daltons.

4 . A method of stimulating an immune response to cancer cells by administration of the cell free extract of claim 1 , together with an appropriate immunological adjuvant.

5 . A method of prophylactically treating a cancer patient by administration of the cell free extract of claim 1 to a patient in need thereof.

6 . A method of inhibiting progression of a preneoplastic lesion to neoplasia by administration of the cell free extract of claim 1 .

7 . A differentiation inducing composition, suitable for administration to a patient in need thereof, derived from placental tissue, the composition produced by the process comprising:

a. extracting human placenta;

b. homogenizing said placenta at a neutral pH, resulting in a homogenate;

c. centrifuging said homogenate in order to free the supernatant of cellular debris;

d. purifying the cell free-debris through adsorption on a C-18 column; and

e. filter sterilizing said composition.

8 . The composition of claim 7 , wherein the homogenized portion of the placenta consists substantially of chorionic tissue.

9 . The composition of claim 7 , wherein a histone deacetylase inhibitor is added directly to the composition.

10 . A method of inducing differentiation and reprogramming of distal cancer lesions through an intratumoral administration of the composition described in claim 7 .

11 . A method of substantially increasing efficacy of the composition of claim 7 by administration in a liposomal complex.

12 . A method of treating a cancer, comprising:

(a) providing the placental cell free extract of claim 1 , wherein said placental cell free extract comprises a cell differentiation associated molecular weight fraction comprising a molecular weight of about 10-10,000 Daltons; and

(b) contacting said placental cell free extract with a cancer cell selected from the group consisting of a leukemia cell, a prostate cancer cell, and a lung cancer cell.

13 . A method of inducing differentiation of a tumor cell, comprising contacting a tumor cell with the placental cell free extract of claim 1 .

14 . A method of inhibiting progression of a neoplasm, comprising providing the placental cell free extract of claim 1 and contacting said neoplasm with said placental cell free extract.

15 . The cell free extract of claim 1 , wherein the method occurs at a neutral pH.

16 . The cell free extract of claim 7 , wherein the method occurs at a neutral pH.

17 . A method of treating a cancer, comprising:

(a) providing the differentiation inducing composition of claim 7 , wherein said differentiation inducing composition comprises a cell differentiation associated molecular weight fraction comprising a molecular weight of about 10-10,000 Daltons; and

(b) contacting said differentiation inducing composition with a cancer cell selected from the group consisting of a leukemia cell, a prostate cancer cell, and a lung cancer cell.

18 . A method of inducing differentiation of a tumor cell, comprising contacting a tumor cell with the placental cell free extract of claim 7 .

19 . A method of inhibiting progression of a neoplasm, comprising providing the placental cell free extract of claim 7 and contacting said neoplasm with said placental cell free extract.

20 . A method of inhibiting progression of a neoplasm, comprising:

providing a placental cell free extract made by the process comprising:

extracting human placenta;

homogenizing said placenta at a neutral pH, resulting in a homogenate;

centrifuging said homogenate in order to free the supernatant of cellular debris; and

purifying the placental cell free extract comprising a cell differentiation associated molecular weight fraction comprising a molecular weight of about 10-10,000 Daltons; and

contacting said placental cell free extract with a neoplastic cell selected from the group consisting of a leukemia cell, a prostate cancer cell, and a lung cancer cell.

21 . A method of inhibiting progression of a neoplasm, comprising:

providing a differentiation inducing composition made by the process of:

extracting human placenta;

homogenizing said placenta at a neutral pH, resulting in a homogenate;

centrifuging said homogenate in order to free the supernatant of cellular debris;

purifying the cell free-debris through adsorption on a C-18 column; and

filter sterilizing said composition to obtain a differentiation inducing composition comprising a cell differentiation associated molecular weight fraction comprising a molecular weight of about 10-10,000 Daltons; and

contacting said differentiation inducing composition with a neoplastic cell selected from the group consisting of a leukemia cell, a prostate cancer cell, and a lung cancer cell.